According to the SEC, from 2007 to 2011, Sanofi KZ engaged in an improper payment scheme to secure public tenders for pharmaceuticals. Sanofi KZ allegedly provided discounts to a distributor, which had won a bid for a public tender for pharmaceuticals. Using that discount, the distributor would kick money back to Sanofi KZ employees, who allegedly then provided the funds to Kazakh officials. From the scheme, Sanofi earned $11,580,099 in profits.
The SEC alleged that Sanofi did not provide sufficient controls or policies over the distributor discounts.
According to the SEC, from 2011 to 2013, Sanofi Levant provided improper sponsorships, gifts, donations, product samples, and consulting, speaking, and clinical trial fees to healthcare providers at publicly and privately owned hospitals in Jordan and other countries. The SEC alleged that the products and services were not properly documented or approved and were intended to induce the health-care providers to increase their purchase and prescription of Sanofi products, and the scheme resulted in approximately $4.2 million in profits.
The Gulf Region
According to the SEC, from 2012 to 2015, Sanofi Gulf engaged in a scheme to submit false expense claims, which were pooled and used to make improper payments to healthcare providers in the private sector to induce them to increase their purchases of Sanofi products.
The SEC alleged that Sanofi Gulf would fabricate or doctor receipts for travel and entertainment expenses that never occurred. The receipts were submitted as legitimate business expenses, which were then pooled and distributed to healthcare providers. From this scheme, Sanofi earned approximately $1.75 million in profits.